KPMG's Deal Capsule Life Sciences Newsletter

Our Newsletter “Deal Capsule Life Sciences” offers regular insights into selected transactions, developments in the M&A market and the issues shaping the transaction landscape of the global life sciences sector – from risk-conscious acquisition strategies to innovation priorities in areas such as oncology and immunology. In addition, our experts provide further insights into market trends and shed light on a specific topic relating to the global transactions and investment market.

Register now:

Archive Issues

Here you will find the past issues of the newsletter, covering selected deals, developments in the M&A market, and the key issues shaping the sector’s transaction market.

Current Issue
Archive

An overview of the topics in the current issue (June 2026)

Deal value and volume: Q1 2026 saw a sharp acceleration in both deal volume and deal value, marking a clear in Life Sciences M&A.
Strategic priority: Private equity investors dominated deal activity, pursuing disciplined, execution‑driven acquisitions targeting assets with revenue visibility, operational leverage, and clearly defined value‑creation pathways.
M&A focus: Deal activity concentrated on late‑stage and near‑commercial assets capable of delivering timely growth and downside protection.
Ruling therapy areas: Oncology and immunology remained the primary focus of dealmaking, while neurology also gained momentum.